SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Rolf A. Stahel

Rolf A. Stahel

ETOP-IBCSG Partners Foundation, Bern

Prof. Rolf A. Stahel is President of the ETOP-IBCSG Partners Foundation in Bern, Switzerland, and remains affiliated with University Hospital Zurich and the University of Zurich. His thoracic oncology research spans EGFR-, ALK- and KRAS-mutated non-small cell lung cancer, malignant pleural mesothelioma, and translational biomarker work. He co-founded the European Thoracic Oncology Platform and its Lungscape registry, led trials including the ETOP BOOSTER study, served as ESMO President, and received the 2025 ESMO Lifetime Achievement Award. He is also Vice-President of the International Cancer Foundation. He is a frequent speaker at major international thoracic oncology congresses.

Connect

Rolf A. Stahel

Featured in

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates